Chugai Pharmaceutical company profile
Company profile
Chugai Pharmaceutical has 5,104 employees and is headquartered in Chuo, Japan.
Chugai Pharmaceutical sells its medicines to customers in Japan and in markets across the world, and it researches, develops, manufactures, imports and exports pharmaceuticals in both. Its product range includes oncology products such as Avastin, Herceptin, Tecentriq, Alecensa, Polivy and Lunsumio, along with Hemlibra, Evrysdi, Mircera, Actemra, Enspryng, PiaSky, Vabysmo and Tamiflu. Among its partnerships, the company is deploying an agentic AI platform with Phylo, Inc. to support biomedical research in drug discovery.
In the fiscal year ended December 2025, revenue reached 1,257.9 billion yen, up 7.5% from the previous year, and net income came to 434.0 billion yen. The company employs 5,104 people. It was founded in 1925 and is headquartered in Chuo, Japan. Formerly known as Chugai Shinyaku Shokai, it took its present name in January 1943, and it is a subsidiary of Roche Holding AG.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Japan
- Headquarters
- Nihonbashi Mitsui Tower, 103-8324, Chuo
- Employees
- 5,104
- Chief executive
- Osamu Okuda
- Founded
- 1925
- Fiscal year
- January - December
- Listing
- 4519 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3519400000
- Website
- chugai-pharm.co.jp
Chugai Pharmaceutical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Chugai Pharmaceutical4519 | Japan | $76.25B | 5,104 | 48.3% | 24.1 |
| Otsuka Holdings4578 | Japan | $41.01B | 37,758 | 18.0% | 17.0 |
| Daiichi Sankyo4568 | Japan | $32.83B | 20,171 | 12.6% | 18.8 |
| Astellas Pharma4503 | Japan | $30.89B | 14,099 | 23.5% | 12.8 |
| CSPC Pharmaceutical Group1093 | Hong Kong SAR China | $11.47B | 18,626 | 27.9% | 10.8 |
| BayerBAYN | Germany | $61.54B | 87,775 | 16.5% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
